|
1
|
Hu Z, Cai M, Zhang Y, Tao L and Guo R:
miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian
cancer by regulating FOXP1/ATG14 pathway. Cell Cycle. 19:193–206.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xiong T, Wang Y, Zhang Y, Yua J, Zhu C and
Jiang W: lncRNA AC005224.4/miR-140-3p/SNAI2 regulating axis
facilitates the invasion and metastasis of ovarian cancer through
epithelial-mesenchymal transition. Chin Med J (Engl).
136:1098–1110. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li F, Zhao C, Diao Y, Wang Z, Peng J, Yang
N, Qiu C, Kong B and Li Y: MEX3A promotes the malignant progression
of ovarian cancer by regulating intron retention in TIMELESS. Cell
Death Dis. 13(553)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gaba F, Blyuss O, Chandrasekaran D,
Bizzarri N, Refky B, Barton D, Ind T, Nobbenhuis M, Butler J, Heath
O, et al: Prognosis following surgery for recurrent ovarian cancer
and diagnostic criteria predictive of cytoreduction success: A
Systematic review and meta-analysis. Diagnostics (Basel).
13(3484)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cheng JT, Wang L, Wang H, Tang FR, Cai WQ,
Sethi G, Xin HW and Ma Z: Insights into biological role of LncRNAs
in epithelial-mesenchymal transition. Cells. 8(1178)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kuang D, Zhang X, Hua S, Dong W and Li W:
Long non-coding RNA TUG1 regulates ovarian cancer proliferation and
metastasis via affecting epithelial-mesenchymal transition. Exp Mol
Pathol. 101:267–273. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Salamini-Montemurri M, Lamas-Maceiras M,
Lorenzo-Catoira L, Vizoso-Vázquez Á, Barreiro-Alonso A,
Rodríguez-Belmonte E, Quindós-Varela M and Cerdán ME:
Identification of lncRNAs deregulated in epithelial ovarian cancer
based on a gene expression profiling meta-analysis. Int J Mol Sci.
24(10798)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhu Y, Zhao Y, Dong S, Liu L, Tai L and Xu
Y: Systematic identification of dysregulated lncRNAs associated
with platinum-based chemotherapy response across 11 cancer types.
Genomics. 112:1214–1222. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zheng ZH, You HY, Feng YJ and Zhang ZT:
LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin
on cisplatin resistance in the colorectal cancer cells. Mol Cell
Biochem. 476:2575–2585. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
He SL, Chen YL, Chen QH, Tian Q and Yi SJ:
LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by
increasing the methylation of EIF2B5 promoter. Mol Med.
28(112)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen P, Sun LS, Shen HM and QU B: LncRNA
KCNQ1OT1 accelerates ovarian cancer progression via
miR-125b-5p/CD147 axis. Pathol Res Pract.
239(154135)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu Y, Wang Y, Yao D and Cui D: LncSOX4
serves an oncogenic role in the tumorigenesis of epithelial ovarian
cancer by promoting cell proliferation and inhibiting apoptosis.
Mol Med Rep. 17:8282–8288. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lan H, Chen W, He G and Yang S: miR-140-5p
inhibits ovarian cancer growth partially by repression of PDGFRA.
Biomed Pharmacother. 75:117–122. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lu Y, Qin T, Li J, Wang L, Zhang Q, Jiang
Z and Mao J: MicroRNA-140-5p inhibits invasion and angiogenesis
through targeting VEGF-A in breast cancer. Cancer Gene Ther.
24:386–392. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cha Y, He Y, Ouyang K, Xiong H, Li J and
Yuan X: MicroRNA-140-5p suppresses cell proliferation and invasion
in gastric cancer by targeting WNT1 in the WNT/β-catenin signaling
pathway. Oncol Lett. 16:6369–6376. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wu Y, Li J, Chen S and Yu Z: The effects
of miR-140-5p on the biological characteristics of ovarian cancer
cells through the Wnt signaling pathway. Adv Clin Exp Med.
29:777–784. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Batra J, Tan OL, O'Mara T, Zammit R, Nagle
CM, Clements JA, Kedda MA and Spurdle AB: Kallikrein-related
peptidase 10 (KLK10) expression and single nucleotide polymorphisms
in ovarian cancer survival. Int J Gynecol Cancer. 20:529–236.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alexopoulou DK, Papadopoulos IN and
Scorilas A: Clinical significance of kallikrein-related peptidase
(KLK10) mRNA expression in colorectal cancer. Clin Biochem.
46:1453–1461. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kato K, Noda T, Kobayashi S, Sasaki K,
Iwagami Y, Yamada D, Tomimaru Y, Takahashi H, Uemura M, Asaoka T,
et al: KLK10 derived from tumor endothelial cells accelerates colon
cancer cell proliferation and hematogenous liver metastasis
formation. Cancer Sci. 115:1520–1535. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Vilming Elgaaen B, Olstad OK, Haug KB,
Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global
miRNA expression analysis of serous and clear cell ovarian
carcinomas identifies differentially expressed miRNAs including
miR-200c-3p as a prognostic marker. BMC Cancer.
14(80)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rakina M, Kazakova A, Villert A, Kolomiets
L and Larionova I: Spheroid formation and peritoneal metastasis in
ovarian cancer: The role of stromal and immune components. Int J
Mol Sci. 23(6215)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chang L, Ni J, Zhu Y, Pang B, Graham P,
Zhang H and Li Y: Liquid biopsy in ovarian cancer: Recent advances
in circulating extracellular vesicle detection for early diagnosis
and monitoring progression. Theranostics. 9:4130–4140.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cheng Z, Chen Y and Huang H:
Identification and validation of a novel prognostic signature based
on ferroptosis-related genes in ovarian cancer. Vaccines (Basel).
11(205)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xu X, Zhuang X, Yu H, Li P, Li X, Lin H,
Teoh JP, Chen Y, Yang Y, Cheng Y, et al: FSH induces EMT in ovarian
cancer via ALKBH5-regulated Snail m6A demethylation. Theranostics.
14:2151–2166. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ojasalu K, Lieber S, Sokol AM, Nist A,
Stiewe T, Bullwinkel I, Finkernagel F, Reinartz S,
Müller-Brüsselbach S, Grosse R, et al: The lysophosphatidic
acid-regulated signal transduction network in ovarian cancer cells
and its role in actomyosin dynamics, cell migration and entosis.
Theranostics. 13:1921–1948. 2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Žilovič D, Vaicekauskaitė I, Čiurlienė R,
Sabaliauskaitė R and Jarmalaitė S: Uterine cavity lavage mutation
analysis in lithuanian ovarian cancer patients. Cancers (Basel).
15(868)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fan W, Xiong R, Zhou Z, Zhang C, Han Y,
Shi T, Qiu J and Zhang R: ZFP57 promotes ovarian cancer progression
by transcriptionally regulating BRCA1 and managing G1 checkpoint. J
Cancer. 14:2039–2050. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang Y and Pei L: Machine learning
constructs a T cell-related signature for predicting prognosis and
drug sensitivity in ovarian cancer. Aging (Albany NY).
16:3332–3349. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chudecka-Głaz A, Strojna A, Michalczyk K,
Wieder-Huszla S, Safranow K, Skwirczyńska E and Jurczak A:
Evaluation of He4 Use in the diagnosis of ovarian cancer: First and
second recurrence, and an analysis of HE4 concentration during
second- and third-line chemotherapy. Diagnostics (Basel).
13(452)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Luo M, Lei R, Zhao Q, Shen Y, He Z and Xu
J: LINC00662 promotes melanoma progression by competitively binding
miR-107 and activating the β-catenin signaling pathway. Int J Med
Sci. 21:265–276. 2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang YY, Deng YX, Yao XT, Luo HH, He WG,
Cao XL, Chen RC, He BC, Jiang HT and Wang J: lncRNA MEG3 promotes
PDK4/GSK-3β/β-catenin axis in MEFs by targeting miR-532-5p. Oxid
Med Cell Longev. 2023(3563663)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zeng Z, Wang J, Xu F, Hu P, Hu Y, Zhuo W,
Chen D, Han S, Wang F, Zhao Y, et al: The m6A modification-mediated
positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc
promotes tumorigenesis of hepatocellular carcinoma. Int J Biol Sci.
20:1744–1762. 2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhan K, Pan H, Zhou Z, Tang W, Ye Z, Huang
S and Luo L: Biological role of long non-coding RNA KCNQ1OT1 in
cancer progression. Biomed Pharmacother. 169(115876)2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yang S, Luo J, Zhang L, Feng L, He Y, Gao
X, Xie S, Gao M, Luo D, Chang K and Chen M: A smart
nano-theranostic platform based on dual-microRNAs guided
self-feedback tetrahedral entropy-driven DNA circuit. Adv Sci
(Weinh). 10(e2301814)2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ye Q, Raese R, Luo D, Cao S, Wan YW, Qian
Y and Guo NL: MicroRNA, mRNA, and proteomics biomarkers and
therapeutic targets for improving lung cancer treatment outcomes.
Cancers (Basel). 15(2294)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang P, Xiong J, Zuo L, Liu K and Zhang H:
miR-140-5p regulates cell migration and invasion of non-small cell
lung cancer cells through targeting VEGFA. Mol Med Rep.
18:2866–2872. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ameres SL, Horwich MD, Hung JH, Xu J,
Ghildiyal M, Weng Z and Zamore PD: Target RNA-directed trimming and
tailing of small silencing RNAs. Science. 328:1534–1539.
2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
de la Mata M, Gaidatzis D, Vitanescu M,
Stadler MB, Wentzel C, Scheiffele P, Filipowicz W and Großhans H:
Potent degradation of neuronal miRNAs induced by highly
complementary targets. EMBO Rep. 16:500–511. 2015.PubMed/NCBI View Article : Google Scholar
|
